EC secures 80M doses of Moderna COVID-19 vaccine

By The Science Advisory Board staff writers

November 25, 2020 -- Moderna has announced that the European Commission (EC) has agreed to secure 80 million doses of its COVID-19 vaccine messenger RNA (mRNA)-1273.

The commission has the option to increase its purchase to up to 160 million doses. The agreement will be finalized after the European Union member states review it. Delivery of the doses could begin as early as the first quarter 2021 if the vaccine is approved by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), which began a rolling review of mRNA-1273 on November 17.

On November 16, it was announced that Moderna's vaccine had a 94.5% efficacy in a phase III clinical trial.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.